Get started
Author

Michael H. J. Rhodin

Observed names: M. Rhodin, M.H.J. Rhodin, Michael H J Rhodin, Michael H. Rhodin, Michael H.J. Rhodin, Michael Rhodin
ORCID: 0000-0003-4032-7545
Observed ORCID: 0000-0003-4032-7545
OpenAlex ID: A5090471054
EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model
2021 · Michael H. J. Rhodin, Nicole V. McAllister, et al. · PLoS Pathogens · 48
PDF
The small molecule inhibitor of SARS-CoV-2 3CLpro EDP-235 prevents viral replication and transmission in vivo
2024 · Michael H. J. Rhodin, Archie C. Reyes, et al. · Nature Communications · 36
PDF
A flexible loop in yeast ribosomal protein L11 coordinates P-site tRNA binding
2010 · Michael H. J. Rhodin, Jonathan D. Dinman · Nucleic Acids Research · 34
PDF
An Extensive Network of Information Flow through the B1b/c Intersubunit Bridge of the Yeast Ribosome
2011 · Michael H. J. Rhodin, Jonathan D. Dinman · PLoS ONE · 32
PDF
A rapid, inexpensive yeast-based dual-fluorescence assay of programmed—1 ribosomal frameshifting for high-throughput screening
2011 · Rasa Rakauskaitė, Pei-Yu Liao, et al. · Nucleic Acids Research · 18
PDF
EDP ‐323, a First‐In‐Class, Once‐Daily, Oral L‐Protein Inhibitor for the Treatment of RSV : Results From a Phase 1 Study in Healthy Adults
2025 · Kimberly Elmore, John DeVincenzo, et al. · Clinical and Translational Science · 10
PDF
The central core region of yeast ribosomal protein L11 is important for subunit joining and translational fidelity
2011 · Michael H. J. Rhodin, Rasa Rakauskaitė, et al. · Molecular Genetics and Genomics · 10
Molecular Basis for Antiviral Action of EDP‐235: A Potent and Selective SARS‐CoV‐2 3CLpro Inhibitor for the Treatment of Covid 19
2022 · Anand Balakrishnan, Archie Reyes, et al. · The FASEB Journal · 8
EDP-938 Has a High Barrier to Resistance in Healthy Adults Experimentally Infected with Respiratory Syncytial Virus
2024 · Rachel Emily Levene, John DeVincenzo, et al. · The Journal of Infectious Diseases · 6
Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239
2016 · Christopher M. Owens, Bradley B. Brasher, et al. · Antimicrobial Agents and Chemotherapy · 5
1213 Cyclophilin Inhibitor Edp-546 Is a Potential Cornerstone Drug for Use in Combination With Ns5a and Protease Inhibitors Due to Its High Barrier to Hcv Resistance
2013 · C.M. Owens, M.H.J. Rhodin, et al. · Journal of Hepatology · 5
Preclinical and Clinical Resistance Profile of EDP-239, a Novel Hepatitis C Virus NS5A Inhibitor
2016 · Christopher M. Owens, Bradley B. Brasher, et al. · Antimicrobial Agents and Chemotherapy · 3
923. EDP-938, A Respiratory Syncytial Virus (RSV) antiviral, demonstrates a high barrier to resistance in a human challenge study
2023 · Rachel E Levene, John DeVincenzo, et al. · Open Forum Infectious Diseases · 1
PDF
1200 Antiviral Activity of Ep-ni266, a Potent Nucleotide Hcv Polymerase Inhibitor
2012 · C.M. Owens, M.H.J. Rhodin, et al. · Journal of Hepatology · 1
EPS-3903 Is a Potent and Selective Oral STAT6 Inhibitor that Blocks Th2 Inflammation in an Ovalbumin Asthma Mouse Model 2253997
2026 · Yaohui Nie, Manuel Roqueta-Rivera, et al. · The Journal of Immunology
Discovery and Characterization of a Potent and Selective Oral Inhibitor of STAT6 for the Treatment of Allergic Diseases 2257118
2026 · Kelsey Garlick, Joyce Sweeney, et al. · The Journal of Immunology
PDF
SARS-CoV-2 resistance pathways to EDP-235
2026 · Kevin Wang, Joyce Sweeney Gibbons, et al. · Antiviral Research
667. Preclinical Pharmacokinetic and Pharmacodynamic Characterization of EDP-938, a Novel and Potent NonFusion Replication Inhibitor of Respiratory Syncytial Virus
2019 · Li-Juan Jiang, Lisha Xu, et al. · Open Forum Infectious Diseases
EDP-494 is a Potent Pan-Genotypic Cyclophilin Inhibitor for HCV Infection, including DAA Resistance Associated Variants (RAVS)
2016 · C. Owens, A. Polemeropoulos, et al. · Journal of Hepatology
1214 Multiple Mutations in Domain Ii of Ns5a Identified in Genotype 2/3 Vital-1 Study Breakthrough Patients Are Required to Reduce Susceptibility to Alisporivir in Vitro
2013 · Chongwon Owens, Michael H. J. Rhodin, et al.
Ribosomal Protein L11: A Cog in the Nanomachine
2011 · Michael H. J. Rhodin · University Libraries (University of Maryland)
Introduction
2006 · Irene Greif, Michael Rhodin · IBM Systems Journal
Works count: 23
Citation count: 217
H-index: 8
I10-index: 7
Year
Topic
Type